Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277207 · ClinicalTrials.gov registry record · Phase 4
Tobacco Cessation Treatment Preferences Among Veteran Smokers
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT05277207: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT05277207 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277207, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
There are significant barriers to tobacco cessation treatment for patients and providers in specialty care clinical settings. Specialty providers cite several barriers to delivering evidence-based tobacco cessation care, including insufficient time and lack of training. In addition, a large proportion of patients who begin tobacco cessation treatment do not quit. Use of healthcare technology (i.e., telehealth, electronic health record, and computerized treatment algorithms based on patient data) to improve patients' ability to quit tobacco use. The purpose of this study is to demonstrate the feasibility of a larger trial, and to evaluate the acceptability of the intervention design. Thirty participants will be assigned to receive either 1) a treatment that includes personalized counseling, tobacco cessation medications, and text messaging; or 2) referral to Department of Veterans Affairs' Quitline program plus SmokefreeVET, a text messaging program.
Primary Outcome
Post-treatment satisfaction will be measured at the 3-month follow-up. Satisfaction will be defined as a mean score greater than 3.5 on the satisfaction measure.
Interventions
- BEHAVIORAL VA Quitline
- BEHAVIORAL Personalized Smoking Cessation Facilitation Meetings
- DRUG Personalized Smoking Cessation Pharmacotherapy
- BEHAVIORAL Personalized Text Messaging Support
- BEHAVIORAL SmokefreeVET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-02 |
| Est. Completion | 2023-09-27 |
| Phase | Phase 4 |
What the finished NCT05277207 record still lists
NCT05277207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which VA Quitline is the first listed.
NCT05277207 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05277207 about?
NCT05277207 is a clinical study titled "Tobacco Cessation Treatment Preferences Among Veteran Smokers". There are significant barriers to tobacco cessation treatment for patients and providers in specialty care clinical settings. Specialty providers cite several barriers to delivering evidence-based tobacco cessation care, including insufficient time and lack of training. In addition, a large proporti...
What is the current status of trial NCT05277207?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2022-05-02. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT05277207?
The interventions under investigation include: VA Quitline (BEHAVIORAL), Personalized Smoking Cessation Facilitation Meetings (BEHAVIORAL), Personalized Smoking Cessation Pharmacotherapy (DRUG), Personalized Text Messaging Support (BEHAVIORAL), SmokefreeVET (BEHAVIORAL).
Who is sponsoring clinical trial NCT05277207?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05277207's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI